Cybin (CYBN) announced a partnership with closely held Segal Trials to support the multinational pivotal phase 3 program for evaluating CYB003 as a treatment for major depressive disorder.

The phase 3 program plans to enroll 550 patients at more 40 clinical sites in the US and Europe, Cybin said Wednesday in a statement.

Segal Trials, the first program member, has six research sites in South Florida with an emphasis on psychiatry, neurology, addiction and psychedelics, Cybin said.

Shares of Cybin rose 4.8% in recent Wednesday trading.

Price: 9.25, Change: +0.42, Percent Change: +4.78